How to Build Trust and Retention in Patient Support Programs

Key Takeaways

• Early patient abandonment signals program underperformance.
• Cumulative treatment burden creates psychological disengagement.
• Metrics must include patient-reported outcomes from launch.
• Data ecosystems should ask right questions, not just look good.
• Trust erosion leads to lower adherence and outcomes.

Summary

Patient support programs (PSPs) are growing alongside specialty drugs, but manufacturers often miss early warning signs of disengagement. Tina Valbh highlights patient abandonment—unanswered calls and missed follow‑ups—as a primary indicator that a program isn’t meeting needs. She argues that many PSPs overlook the cumulative treatment burden patients endure before enrollment, leading to psychological barriers and drop‑outs. By shifting metrics to include patient‑reported outcomes and real‑world experiences from day one, manufacturers can create trust‑focused ecosystems that improve adherence and outcomes.

Pulse Analysis

The rapid expansion of specialty medications has forced pharmaceutical companies to invest heavily in patient support programs, yet many of these initiatives remain reactive rather than proactive. Valbh points out that abandonment—patients not answering calls or missing scheduled touchpoints—often surfaces before any formal metrics flag a problem. This early disengagement is frequently rooted in the extensive, often traumatic, treatment journeys patients endure before reaching a PSP, such as chemotherapy, surgeries, and radiation. Ignoring this cumulative burden creates hidden psychological barriers that erode trust and drive drop‑outs.

To counteract these pitfalls, manufacturers must redesign their data ecosystems to prioritize patient‑reported outcomes (PROs) alongside traditional adherence metrics. Integrating real‑world experience data from the moment a drug launches enables teams to identify friction points—like confusing prior‑authorization processes or inadequate education on oral oncolytics—before they translate into abandonment. By asking the right questions—how patients feel, what obstacles they face, and what support they truly need—companies can shift from checklist‑driven dashboards to patient‑centered platforms that deliver timely, personalized interventions.

The strategic payoff of such a transformation is significant. Trust‑based PSPs not only improve medication adherence but also enhance brand perception, reduce costly churn, and generate richer data for future product launches. As the specialty market becomes increasingly competitive, manufacturers that embed patient insight into the core of their support infrastructure will differentiate themselves, secure higher market share, and ultimately drive better health outcomes for the patients they serve.